SEC Comment Letter 0000000000-24-006053 to Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: May 24, 2024 · CIK: 0001533040 · Accession: 0000000000-24-006053
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279557
Letter
United States securities and exchange commission logo May 24, 2024 Caitlin Kontulis Vice President, Finance and Administration Phio Pharmaceuticals Corp. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed May 20, 2024 File No. 333-279557 Dear Caitlin Kontulis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steve Abrams
Show Raw Text
United States securities and exchange commission logo
May 24, 2024
Caitlin Kontulis
Vice President, Finance and Administration
Phio Pharmaceuticals Corp.
11 Apex Drive, Suite 300A, PMB 2006
Marlborough, MA 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-3
Filed May 20, 2024
File No. 333-279557
Dear Caitlin Kontulis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steve Abrams